Emerging biological roles for erythropoietin in the nervous system
The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.
Abstract
Erythropoietin mediates an evolutionarily conserved, ancient immune response that limits damage to the heart, the nervous system and other tissues following injury. New evidence indicates that erythropoietin specifically prevents the destruction of viable tissue surrounding the site of an injury by signalling through a non-haematopoietic receptor. Engineered derivatives of erythropoietin that have a high affinity for this receptor have been developed, and these show robust tissue-protective effects in diverse preclinical models without stimulating erythropoiesis. A recent successful proof-of-concept clinical trial that used erythropoietin to treat human patients who had suffered a stroke encourages the evaluation of both this cytokine and non-erythropoietic derivatives as therapeutic agents to limit tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [2150]
Citations
Cites
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402 · cited 1×
“Follow-up studies confirmed erythropoietin to be a neuroprotective factor in hypoxic-ischaemic, traumatic, excitotoxic and inflammatory injurie”
BackgroundSelf-citationHIF-1 and mechanisms of hypoxia sensing
Semenza, G. L. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00194-0 · Cited by 1,268
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250 · cited 1×
“It is worrying that some cancer patients treated with rhEPO have also shown tumour expansio”
BackgroundErythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,028
Self-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
Sirén, A.-L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051606598 · Cited by 1,019
Self-citationIn vivo evidence that erythropoietin protects neurons from ischemic damage
Sakanaka, M., Wen, T.-C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., & Sasaki, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4635 · Cited by 949 · cited 1×
“Follow-up studies confirmed erythropoietin to be a neuroprotective factor in hypoxic-ischaemic, traumatic, excitotoxic and inflammatory injurie”
BackgroundDigicaylioglu, M., & Lipton, S. A. (2001) · Nature · doi:10.1038/35088074 · Cited by 923 · cited 1×
“Furthermore, although it has been reported that STAT is part of erythropoietin's neuroprotective signalling cascade in vitro , in vivo studies largely have not supported the involvement of STATs in erythropoietin cytoprotectio”
BackgroundPurification of human erythropoietin.
Miyake, T., Kung, C. K., & Goldwasser, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)63387-9 · Cited by 886
Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) · Science · doi:10.1126/science.1098313 · Cited by 803
Self-citation
Cited by
Items 401–500 of 527
Use of Erythropoietin and Fibrin Glue Mixture for Peripheral Nerve Repair
Erdal, A. I., Fındıkçıoğlu, K., Karasu, O., Özkoçer, S. E., & Elmas, Ç. (2021) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000008796 · Cited by 6
The potential of erythropoietin to treat asphyxia in newborns
Juul, S. E., & Pet, G. C. (2014) · Research and Reports in Neonatology · doi:10.2147/rrn.s52375 · Cited by 8
Antidepressant-like effects of erythropoietin : a focus on behavioural and hippocampal processes
Osborn, M. (2012) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2012-07424 · Cited by 6
Erythropoietin relieves neuronal apoptosis in epilepsy rats via TGF-β/Smad signaling pathway
Pan, X., Gong, X., Pan, L., & Lu, L. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.10.35 · Cited by 5
Evaluating Effects of EPO in Rodent Behavioral Assays Related to Depression
Duman, C. H., & Newton, S. S. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-308-4_8 · Cited by 5
Construction of an Erythropoietin-Expressing Bioartificial Renal Tubule Assist Device
Sun, J., Wang, C., Zhu, B. L., Larsen, S. H., Wu, J., & Zhao, W. (2011) · Renal Failure · doi:10.3109/0886022x.2010.536605 · Cited by 5
Brain metastases and treatment: multiplying cognitive toxicities
Nassif, E. F., Arsene-Henry, A., & Kirova, Y. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1582336 · Cited by 6
Granulomatous and nongranulomatous neurological sarcoidosis
Tavee, J. O., & Voortman, M. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10032020 · Cited by 6
Rjiba-Touati, K., Ayed‐Boussema, I., Belarbia, A., Guedri, Y., Zakhama, A., Achour, A., & Bacha, H. (2012) · Human & Experimental Toxicology · doi:10.1177/0960327111428957 · Cited by 5
“rhEPO administration decreased tissue damage by inhibition of apoptosis, reduction of inflammatory cytokines, maintenance of vascular flow through, increase of nitric oxide synthesis and decrease of lipid peroxidation.(31,33) In the present study, we demonstrated that rhEPO has a preventive effect against Cisp-induced…”
BackgroundWüstefeld, L., Winkler, D., Janc, O. A., Hassouna, I. A., Ronnenberg, A., Ostmeier, K., Müller, M., Brose, N., Ehrenreich, H., & Wojcik, S. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13445 · Cited by 5
Aachmann‐Andersen, N. J., Christensen, S. J., Lisbjerg, K., Oturai, P., Johansson, P. I., Holstein‐Rathlou, N., & Olsen, N. V. (2018) · Physiological Reports · doi:10.14814/phy2.13573 · Cited by 5
Kreisman, N. R., Wooliscroft, L., Campbell, C. F., Dotiwala, A. K., Cox, M. L., Denson, A. C., Betancourt, A. M., & Tomchuck, S. L. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146517 · Cited by 6
Rjiba-Touati, K., Ayed‐Boussema, I., Belarbia, A., Mokni, M., Achour, A., Bacha, H., & Abid, S. (2014) · Human & Experimental Toxicology · doi:10.1177/0960327114550885 · Cited by 5
“Several studies demonstrated that rhEPO administration decreased tissue damage by inhibition of apoptosis, reduction of inflammatory cytokines, maintenance of vascular flow through, increase of nitric oxide synthesis, and decrease of lipid peroxidation.(23,24) In this study, we demonstrated that rhEPO has a preventive…”
BackgroundPotential of Novel EPO Derivatives in Limb Ischemia
Joshi, D., Tsui, J. C. S., Yu, R. S. H., Shiwen, X., Selvakumar, S., Abraham, D., & Baker, D. (2012) · Cardiology Research and Practice · doi:10.1155/2012/213785 · Cited by 5
Brain Delivery of Antibody-Derived Biologicals for Alzheimer’s Disease: An Updated Narrative Review
Sumbria, R. K., & Boado, R. J. (2026) · Antibodies · doi:10.3390/antib15020037 · Cited by 5
Chang, R., Chandrashekar, D. V., Roules, G. C., Jagadeesan, N., Iwasaki, E., Oyegbesan, A., Davtyan, H., & Sumbria, R. K. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100459 · Cited by 5
“EPO modulates key events involved in AD pathogenesis, including A β load, tau hyperphosphorylation, and endogenous neuroprotective and neuroregenerative pathways (Brines and Cerami, 2005).”
Carbamylated erythropoietin enhances mice ventilatory responses to changes in O2 but not CO2 levels
Khemiri, H., Maresca, M., & Gestreau, C. (2016) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2016.06.002 · Cited by 4
“…demonstrating that H. Khemiri et al. / Respiratory Physiology o fl t tion and in response to moderate hypoxia (10% O ) 2 h after acute F s V m v o nhanced the ventilatory depression seen in hyperoxia. nly a fraction of circulating rhEPO could reach the cerebrospinal uid (Brines and Cerami, 2005).”
BackgroundThe lack of CD131 and the inhibition of Neuro-2a growth by carbamylated erythropoietin
Ding, J., Li, Q., Yu, J., Wang, X., Lü, C., Ma, C., & Xiao, B. (2015) · Cell Biology and Toxicology · doi:10.1007/s10565-015-9292-y · Cited by 5
Marelli, A., Czornyj, L. A., Rocha, L., & Lazarowski, A. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6355-3_8 · Cited by 4
Bringas-Vega, M. L., Liu, S., Zhang, M., Ibáñez, I. P., Chacón, L. M. M., García, L. G., Bocourt, V. P., Jahanshahi, M., & Valdes-Sosa, P. A. (2020) · Parkinson s Disease · doi:10.1155/2020/8625794 · Cited by 4
“extends to PD the evidence for neuroprotective properties of rHuEPO already described in other neurologic diseases [5] and is supported by the antiapoptotic, anti-inflammatory, and cytoprotective effects of EPO in PD animal models [6, 7].”
BackgroundAntidepressant-like effects of trophic factor receptor signaling
Sathyanesan, M., & Newton, S. S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.958797 · Cited by 4
“When studies began reporting on the CNS effects of EPO in the late 1990s, it was already an FDA approved (in 1989) anemia drug (Genc et al., 2004; Brines and Cerami, 2005).”
BackgroundErythropoietin Improves Cardiovascular Function in Adult Rats After Acute Hemorrhage
Puchulu, M. B., Arreche, N., Zotta, E., Donato, M., Ogonowski, N. S., Fellet, A. L., & Balaszczuk, A. M. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000666 · Cited by 3
Bernardo, V. S., Torres, F. F., Chaves, N. A., Okumura, J. V., da Silva, D. G. H., & Bonini-Domingos, C. R. (2020) · Meta Gene · doi:10.1016/j.mgene.2020.100660 · Cited by 3
Almaguer‐Melian, W., Mercerón‐Martínez, D., Alberti‐Amador, E., Alacán‐Ricardo, L., de Bardet, J. C., Orama‐Rojo, N., Pina, A. B., Herrera-Estrada, I., & Bergado, J. A. (2023) · Synapse · doi:10.1002/syn.22282 · Cited by 3
“Erythropoietin(EPO),akidneyhormoneinresponsetohypoxia,couldbeone of those mechanisms (Brines & Cerami, 2005).”
Garrido, P., Reis, F., Costa, E. M., Almeida, A., Parada, B., Teixeira‐Lemos, E., Santos, P., Alves, R., Sereno, J., Pinto, R. M. A., et al. (2010) · The Open Drug Discovery Journal · doi:10.2174/1877381801002020025 · Cited by 3
Neurologic Complications of Chronic Kidney Disease
Murray, A. M., Seliger, S. L., & Stendahl, J. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00021-4 · Cited by 5
Ameliorating effect of erythropoietin in a severe case of COVID-19: case report
Maufak, M. M., Khan, G., Purushothaman, A., Ahamed, F., Jallo, M. K. I., Rizwan, M., Kumar, S., Almansouri, A., Almansoori, T. M., & Ouseppachen, M. T. (2022) · Pan African Medical Journal · doi:10.11604/pamj.2022.43.129.35014 · Cited by 3
Vasculoprotective Effects of Erythropoietin
Kiernan, T. J., & Simari, R. D. (2006) · Circulation Research · doi:10.1161/01.res.0000228463.96905.45 · Cited by 3
Correction: Emerging biological roles for erythropoietin in the nervous system
Brines, M. L., & Cerami, A. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1739 · Cited by 3
Self-citationTherapeutic effect of erythropoietin and its derivatives in the treatment of acute ischemic stroke
Rama, R., & Torrella, J. R. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.1004101 · Cited by 2
Vats, T., Saha, T., & Mehan, S. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00320-2 · Cited by 2
Ghadirzadeh, E., Sari, S. P. S. M., Saed, S., Gheibi, M., Rad, A. A., Bidrouni, S. R., Mohseni, G., & Siahposht-Khachaki, A. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115943 · Cited by 2
Erythropoietin—A Hematopoietic Hormone with Emerging Diverse Activities
Prutchi‐Sagiv, S., Mittelman, M., & Neumann, D. (2006) · Elsevier eBooks · doi:10.1016/b978-012369442-3/50197-5 · Cited by 2
Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients
Costa, E. M., Belo, L., & Santos‐Silva, A. (2011) · InTech eBooks · doi:10.5772/24178 · Cited by 2
Colella, P., & Auricchio, A. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-308-4_16 · Cited by 2
Ohana, Y. H., Liron, T., Prutchi‐Sagiv, S., Mittelman, M., Souroujon, M. C., & Neumann, D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00221-9 · Cited by 3
Fioranelli, M., & Guglielmo Marconi University (2015) · Clinical Case Reports and Reviews · doi:10.15761/ccrr.1000118 · Cited by 2
Erythropoietic neuroprotection: Holy Grail or potential to fail?
Pavenski, K., Hare, G. M. T., & Mazer, C. D. (2011) · Intensive Care Medicine · doi:10.1007/s00134-011-2305-2 · Cited by 2
Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?
Butsch, P. O., & Cudkowicz, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.04.001 · Cited by 2
Studies on aquaporin 4, a molecular determinant of brain water homeostasis
Gunnarson, E. (2006) · Figshare · Cited by 2
Effects of recombinant human erythropoietin in the cuprizone mouse model of de- and remyelination
Hagemeyer, N. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1472 · Cited by 2
Biological and physical strategies to improve the therapeutic index of photodynamic therapy.
Rendon, C. A. (2008) · TSpace (University of Toronto) · Cited by 2
Bianchi, R., Lombardi, R., Porretta‐Serapiglia, C., & Lauria, G. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-308-4_13 · Cited by 1
Demir, S., Fernández, M., Daly, W., Al-Waeel, M., Abbah, S. A., Quinlan, L. R., Windebank, A. J., Wang, H., & Pandit, A. S. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100312 · Cited by 1
Erythropoiesis Stimulation in Acute Ischemic Syndromes
Ruifrok, W.-P. T., Lipšic, E., de Boer, R. A., van Gilst, W. H., & van Veldhuisen, D. J. (2010) · Heart Failure Clinics · doi:10.1016/j.hfc.2009.12.002 · Cited by 1
Berendsen, R. R., Lindeman, R. C., Boom, M., Aarts, L. P. H. J., van Dorp, E. L. A., & Teppema, L. J. (2016) · Experimental Physiology · doi:10.1113/ep085675 · Cited by 2
Brain Poster Session: Neuroprotection
(2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.156 · Cited by 1
Endogenous Agents That Contribute to Generate or Prevent Ischemic Damage
Piazza, O., & Scarpati, G. (2012) · InTech eBooks · doi:10.5772/32745 · Cited by 1
Development of Latent Cytokine Fusion Proteins
Mullen, L., Adams, G., Fatah, R., Gould, D., Rigby, A., Sclanders, M., Koutsokeras, A., Mittal, G., Vessillier, S., & Chernajovsky, Y. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch16 · Cited by 1
Effects of Erythropoietin in Murine-Induced Pluripotent Cell-Derived Panneural Progenitor Cells
Offen, N., Flemming, J., Kamawal, H., Ahmad, R., Wolber, W., Geis, C., Zaehres, H., Schöler, H. R., Ehrenreich, H., Müller, A. M., et al. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00136 · Cited by 1
Osherovich, L. Z. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.35 · Cited by 1
Meshkini, A., تبریز, Salehpour, F., تبریز, Pourhajshokr, N., تبریز, Motlagh, P. S., تبریز, Ghojazadeh, M., & تبریز (2015) · Iranian Journal of Neurosurgery · doi:10.18869/acadpub.irjns.1.2.17 · Cited by 1
Activin A Reduces Brain Injury After Stroke
Mukerji, S. S. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Moradi, M., Saidijam, M., Ghaleiha, A., Jahangard, L., Yadegarazari, R., & Keshavarzi, A. (2019) · Neurochemical Journal · doi:10.1134/s1819712419020089 · Cited by 1
Neurotropic Effect of Carbamylated Darbepoietin on the Model of Primary Hippocampal Culture
Shirokova, O. M., Sokolov, R. A., Александровна, К. С., Pershin, V. I., Ermin, K. V., Glyavina, M. M., Жученко, М. А., ANDREEVA, N. N., Щелчкова, Н. А., & Mukhina, I. V. (2019) · Современные технологии в медицине · doi:10.17691/stm2019.11.4.10 · Cited by 1
Neurologic Complications of Chronic Kidney Disease
Seliger, S. L., & Waddy, S. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00029-2 · Cited by 3
From bench to bedside: Neuroprotective effects of erythropoietin
Ehrenreich, H., & Bartels, C. (2008) · Springer eBooks · doi:10.1007/978-3-211-69459-6_32 · Cited by 1
Cheung, H. W., Wong, K., Tam, J. C. L., Farrington, A. F., Bond, A. J., Wan, T. S. M., & Ho, E. N. M. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3810 · Cited by 1
Complementary and Alternative Medicine and NTOS
Ellis, W., & Illig, K. A. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4366-6_26 · Cited by 1
Jin, H. Y., Jeung, S. J., Kim, C. H., Park, J. H., Baek, H. S., & Park, T. S. (2007) · The Journal of Korean Diabetes Association · doi:10.4093/jkda.2007.31.2.151 · Cited by 1
Gorio, A., Marfia, G., Bottai, D., & Giulio, A. M. D. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00701-4 · Cited by 1
Aerobic exercise training for improving robustness of Atlantic salmon (Salmo salar)
Castro, V. (2012) · NVA (Nasjonalt vitenarkiv) · Cited by 1
Bringas-Vega, M. L., Liu, S., Zhang, M., Ibáñez, I. P., Chacón, L. M. M., García, L. G., Bocourt, V. P., Jahanshahi, M., & Valdes-Sosa, P. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/864397 · Cited by 1
The EPO/EPOR system in the brain: Search for mechanisms of action
Dahm, L. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4465 · Cited by 1
Damgaard, V., Schandorff, J. M., Johansen, A., Macoveanu, J., Cramer, K., Østergaard, I. P., Thommesen, K. K., Bruun, C. F., Meyer, M., Plavén‐Sigray, P., et al. (2026) · medRxiv · doi:10.64898/2026.06.28.26356414 · Cited by 1
Current Advances in Cerebral Malaria Associated Encephalopathy
Liu, M., Guo, S., Battle, M., & Jonathan, K. (2012) · InTech eBooks · doi:10.5772/30739
Tiedemann, J. (2012) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-12132
Signalling of hematopoietic growth factors in mammalian neural cells
Byts, N. (2007) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3261
Stroke: Mechanisms of Excitotoxicity and Approaches for Therapy
O’Neill, M. J., Lodge, D., & McCulloch, J. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn058
Chapter 7 Gene induction, protein synthesis, and related issues
Hakim, A. M., & Thompson, C. S. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(08)01907-6
Fevre, M. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Tissue Protection and Regeneration Aided by Erythropoietin and Erythropoietin-derived Peptides
Fliser, D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380928-5.10005-3
Sargin, D. (2009) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3247
Hematopoietic Growth Factor Family for Stroke Drug Development
Solaroğlu, İ., & Digicaylioglu, M. H. (2012) · Springer eBooks · doi:10.1007/978-1-4419-9530-8_12
“Activation of these cascades subsequently activates their downstream substrates and affects target genes which regulate erythropoiesis [ 10 ] .”
BackgroundInfluentialL'érythropoïétine : un traitement de l'oedème cérébral de l'hypoxie cérébrale post-traumatiques
Bouzat, P. (2013) · theses.fr (ABES) · doi:10.70675/938b1493zb8b4z44fbzb866z3c99702b9e4e
Miskowiak, K. W., Favaron, E., Hafizi, S., Inkster, B., Cowen, P. J., Goodwin, G. M., & Harmer, C. J. (2009) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(09)70081-1
Characterization of the Sleeping Beauty transposon system for gene therapy applications
Score, P. R. (2008) · University of Minnesota Digital Conservancy (University of Minnesota)
Response to Letter by Genc et al
Stetler, R. A., Chen, J., & Cao, G. (2010) · Stroke · doi:10.1161/strokeaha.110.593574
Laboratory Animal Science – Main focus: Neuroscience
Nebendahl, K., & Kimmina, S. (2007) · GRO · doi:10.17875/gup2007-391
Ehrenreich, H., Bartels, C., Krampe, H., & Begemann, M. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_13
Influence of Kidney Transplantation on Cognitive Function in End - Stage Kidney Disease Patients
(2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608057351113010010
Trauma Surgery 1 Early management of severe traumatic brain injury
Rosenfeld, J. V., Bragge, P., Morganti-Kossmann, M. C., Gruen, R. L., & Rosenfeld, J. R. V. (2012)
Go, S. S. C., Adamowicz‐Salach, A., Albrecht, K., & Sobocińska-Mirska, A. (2011)
NOVEL APPROACHES TO MODELING AND TREATMENT OF COGNITIVE DEFICITS IN NEUROPSYCHIATRIC DISEASES
El-Kordi, A. (2010) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-389
Erythropoietin in post-resuscitation neurological recovery: is there light at the end of the tunnel?
Kupnik, D., & Grmec, Š. (2007) · Signa Vitae · doi:10.22514/sv21.042007.2
Avaliação do efeito da interleucina-6 e da eritropoetina na lesão medular em ratos
de Barros, A. G. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2018.tde-15032018-093626
Pharmacological Interventions in Acute Kidney Injury
Okusa, M. D., & Balogun, R. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0987-2.00049-2
Bringas-Vega, M. L., Liu, S., Zhang, M., Ibáñez, I. P., Chacón, L. M. M., García, L. G., Bocourt, V. P., Jahanshahi, M., & Valdes-Sosa, P. A. (2019) · Greater South Information System · doi:10.60692/7ac5b-s3039
Functional characterization of Frataxin isoforms and mechanisms of regulation of frataxin expression
Agrò, M. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Wakhloo, D. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7758
The burden of neurosarcoidosis and small fiber neuropathy associated symptoms
Voortman (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20191129mv
Hahn, N. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7774
Recent Developments in Treating Cognitive Impairment Associated with SchizophreniaPreprint
Bittner, R. A., Barnes-Scheufler, C. V., Hettwer, M. D., Reif, A., & Qubad, M. (2021) · Preprints.org · doi:10.20944/preprints202105.0257.v1
Baloyannis, S. J. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98436
Erythropoietin-mediated neuroprotection in insects
Miljus, N. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5834
Pharmacological Interventions in Acute Kidney Injury
Chopra, T., Balogun, R. A., & Okusa, M. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00048-3
Anti-apoptotic and neuroprotective erythropoietin/CRLF3-signalling in insects and humans
Knorr, D. Y. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9287
A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19
EmamiPari, F., Kamali, S., Nikzad, G., Navi, N. R., Soltani, S., & Kalani, M. R. (2022) · Journal of Clinical and Basic Research · doi:10.52547/jcbr.6.1.11
Metadata
- Authors
- Brines, M., & Cerami, A.
- Corresponding author
- Brines, Michael
- Venue
- Nature Reviews Neuroscience
- Published
- 2005-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 484-494
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2168867226
- Cited by
- 523
- References
- 108
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 6 · 2023: 8 · 2022: 18 · 2021: 21 · 2020: 13 · 2019: 25 · 2018: 17 · 2017: 16 · 2016: 21 · 2015: 19 · 2014: 22 · 2013: 30 · 2012: 38
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Update notices
- correction (2005-08-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- www.springer.com/tdm (unspecified)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heme Oxygenase-1 and Carbon Monoxide
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- erythropoietin, nervous system, neuroprotection, tissue damage, stroke, neuroinflammation
- MeSH terms
- Animals, Central Nervous System, Erythropoietin, Humans, Signal Transduction, Receptors, Cytokine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.